EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma

Molecular Carcinogenesis
Lingrui SuHaitao Shen

Abstract

Glioblastoma (GBM) is the most common and malignant brain tumor in adults. Recently, programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint blockades have been applied for GBM treatment. However, the mechanism of PD-L1 upregulation in GBM is still unclear. COP9 signalosome 6 (CSN6) is crucial for maintaining the protein stabilization in cancer cells. In this study, we applied human GBM specimens and cell lines to investigate whether the EGFR-ERK pathway regulates CSN6 for PD-L1 upregulation. Data from The Cancer Genome Atlas dataset showed that high expression of EGFR, CSN6, and PD-L1 in patients with glioma was associated with poor prognosis. In 47 human GBM specimens, high expression of PD-L1 was associated with low amount of CD8+ T cell infiltration as well as the poor prognosis of patients. CSN6 was positively correlated with EGFR and PD-L1 expression in human GBM specimens. We treated two GBM cell lines (U87 and U251) with epidermal growth factor (EGF) in vitro, and found EGF-upregulated p-EGFR, p-ERK, CSN6, and PD-L1 expression in GBM cells. PD98059, the ERK blocker, inhibited upregulations of CSN6 and PD-L1 in EGF-treated cells. Inhibition of CSN6 by small interfering RNA decreased PD-L1 expression but also...Continue Reading

References

Oct 23, 2003·Annual Review of Cell and Developmental Biology·Ning Wei, Xing Wang Deng
May 1, 2008·Annual Review of Plant Biology·Sara K Hotton, Judy Callis
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Oct 26, 2012·Cell Cycle·Yuwen XueMong-Hong Lee
Dec 24, 2013·Clinical Neuropathology·Anna Sophie BerghoffMatthias Preusser
Jul 22, 2014·Nature·Gondichatnahalli M LingarajuNicolas H Thomä
Oct 31, 2014·Neuro-oncology·Anna Sophie BerghoffWolfgang Wick
Nov 15, 2014·Nature Communications·Jian ChenMong-Hong Lee
Nov 16, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Peter E FecciJohn H Sampson
Feb 13, 2015·Biomedical Journal·Ya-Shan Chen, Chia-Rui Shen
Aug 28, 2015·Expert Review of Anticancer Therapy·Elnaz FaghfuriMohammad Abdollahi
Nov 22, 2016·Cancer Cell·Seung-Oe LimMien-Chie Hung
Feb 1, 2017·Nature Reviews. Immunology·Thomas Korn, Axel Kallies
Feb 9, 2017·Oncotarget·Dieter Henrik HeilandOliver Schnell
May 16, 2017·The Journal of Surgical Research·Jun-Te HsuTa-Sen Yeh
Dec 17, 2017·Immunity·Matthew A CoelhoJulian Downward
May 31, 2018·Journal of Experimental & Clinical Cancer Research : CR·Feng XuChaoliu Dai
Jun 19, 2018·Frontiers in Pharmacology·Yiting WangJie Xu
Aug 19, 2018·Cancer Immunology, Immunotherapy : CII·Yongyu Shi
Oct 4, 2018·Nature·Heidi LedfordMatthew Warren
Nov 1, 2018·Journal of Experimental & Clinical Cancer Research : CR·Anand RotteMadhuri Bhandaru

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.